2026-04-17T12:07:56Zhttps://recercat.cat/oai/request
oai:recercat.cat:2072/4274632026-03-13T04:35:50Zcom_2072_98col_2072_378192
RECERCAT author Vivanco-Hidalgo, Rosa Maria author Gómez González, Alejandra author Moreira Villanueva, Antía author Díez, Laura author Elosua, Roberto author Roquer González, Jaume 2017 Altres ajuts: MSC/RD12-0042-0020Altres ajuts: MSC/RD12/0042/0013Epilepsy has been associated with cardiovascular comorbidity. This study aimed to assess the potential association between cardiovascular risk factors (s), antiepileptic drugs (s), and etiology. A single-center retrospective epilepsy cohort from the decade of 2004-2013 was assessed. Poisson regression models with robust variance were estimated to obtain prevalence ratios () according to prescription and etiology. After excluding patients in the monotherapy group with vascular etiology or previous cardiovascular events, in the remaining 400 patients, enzyme-inducer s (s), especially phenytoin (), were associated with higher prevalence of dyslipidemia (a 1.77, p < .05), compared to valproic acid. No etiology was associated with higher prevalence of any . Patients treated with s, especially , had higher prevalence of dyslipidemia. open access Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. https://creativecommons.org/licenses/by/4.0/ Antiepileptic drugs Cardiovascular risk factors Comorbidity Epilepsy Prevalence of cardiovascular risk factors in people with epilepsy Article